

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Upadacitinib 30 mg extended-release (Rinvoq 30 mg ER)

Notes:

- Quantity Limits: Yes
- Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- ^ Adequate trial is defined as the following:
 - Topical corticosteroids – 8 weeks
 - Topical calcineurin inhibitors – 6 weeks
 - Phototherapy – 8 weeks
 - Atopic dermatitis systemic medications – 6 weeks
 - Biologics for inflammatory bowel disease – 12 weeks

Initiation (new start) criteria and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:

Non-formulary **upadacitinib 30 mg extended-release (Rinvoq 30 mg ER)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

1. Prescriber is a gastroenterologist and patient has a diagnosis of ulcerative colitis or Crohn's disease
 - Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
 - Patient had an inadequate response to upadacitinib 15 mg extended-release (criteria based) once daily as determined by prescriber
2. Prescriber is a dermatologist and patient has a diagnosis of moderate to severe atopic dermatitis
 - Patient is at least 12 years of age and weights at least 40 kilograms
 - Patient has tried and failed an adequate trial[^] of, or patient has an allergy or intolerance to the following medications
 - At least 1 medium to super-potent/ultrahigh potency topical corticosteroid
 - At least 1 topical calcineurin inhibitor
 - Patient has tried and failed narrow-band ultraviolet B (NB-UVB) phototherapy (unless documented by prescriber phototherapy not appropriate)
 - Patient has tried and failed an adequate trial[^] of, or patient has an allergy or intolerance to at least 1 of the following systemic medications (or contraindication to all)
 - Azathioprine

kp.org

Revised: 01/11/24
Effective: 03/07/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Upadacitinib 30 mg extended-release (Rinvoq 30 mg ER)

- Cyclosporine
- Methotrexate
- Mycophenolate
- Patient has tried and failed/intolerant to tralokinumab-ldrm (criteria based) OR dupilumab (criteria based)
- Patient had an inadequate response to upadacitinib 15 mg extended-release (criteria based) once daily as determined by prescriber
- Patient is NOT currently on a Janus kinase inhibitor (oral or topical) or biologic (tralokinumab-ldrm or dupilumab) for atopic dermatitis

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary upadacitinib 30 mg extended-release (Rinvoq 30 mg ER) will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

1. Prescriber is a gastroenterologist and patient has a diagnosis of ulcerative colitis or Crohn's disease
 - Patient has responded to upadacitinib treatment as determined by prescriber
2. Prescriber is a dermatologist and patient has a diagnosis of moderate to severe atopic dermatitis
 - Patient has responded to upadacitinib treatment as determined by prescriber
 - Patient is NOT currently on a Janus kinase inhibitor (oral or topical) or biologic (tralokinumab-ldrm or dupilumab) for atopic dermatitis

kp.org

Revised: 01/11/24
Effective: 03/07/24

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest